Skip to main content

Table 3 Fractures by BMD classification at baseline (on or before day 1), Asian and Caucasian

From: Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy

  

Tibolone 2.5 mg

Placebo

All

  

n

Number of fractures

%

n

Number of fractures

%

n

Number of fractures

%

Asian

All

133

6

4.5

127

8

6.3

260

14

5.4

 

Osteoporosis

27

1

3.7

25

2

8.0

52

3

5.8

 

Osteopenia

75

4

5.3

64

5

7.8

139

9

6.5

 

Normal

31

1

3.2

38

1

2.6

69

2

2.9

Caucasian

All

206

7

3.4

221

17

7.7

427

24

5.6

 

Osteoporosis

12

0

0.0

17

2

11.8

29

2

6.9

 

Osteopenia

85

4

4.7

86

8

9.3

171

12

7.0

 

Normal

109

3

2.8

118

7

5.9

227

10

4.4

All

All

339

13

3.8

348

25

7.2

687

38

5.5

 

Osteoporosis

39

1

2.6

42

4

9.5

81

5

6.2

 

Osteopenia

160

8

5.0

150

13

8.7

310

21

6.8

 

Normal

140

4

2.9

156

8

5.1

296

12

4.1

  1. No significant reduction in fractures occurred in the group overall, although an almost-significant reduction occurred in Caucasian patients taking tibolone (p = 0.054). Fractures according to baseline bone mineral density (BMD) classification: The percentage of women who developed bone fractures did not differ between those with osteoporosis and osteopenia, but because osteopenia was the larger population group, more fractures occurred among osteopenic patients.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us